Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donanemab (LY3002813) dose-escalation study in Alzheimer's disease.
Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Shcherbinin S, Ardayfio P, Sims JR. Lowe SL, et al. Among authors: chua l. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112. eCollection 2021. Alzheimers Dement (N Y). 2021. PMID: 33614890 Free PMC article.
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging.
Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, Lo AC, Fleisher AS, Dage JL, Ardayfio P, Aguiar G, Ishibai M, Takaichi G, Chua L, Mullins G, Sims JR. Lowe SL, et al. Among authors: chua l. J Prev Alzheimers Dis. 2021;8(4):414-424. doi: 10.14283/jpad.2021.56. J Prev Alzheimers Dis. 2021. PMID: 34585215 Clinical Trial.
Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease.
Gueorguieva I, Willis BA, Chua L, Chow K, Ernest CS 2nd, Wang J, Shcherbinin S, Sims JR, Chigutsa E. Gueorguieva I, et al. Among authors: chua l. Alzheimers Dement (N Y). 2023 Jun 28;9(2):e12404. doi: 10.1002/trc2.12404. eCollection 2023 Apr-Jun. Alzheimers Dement (N Y). 2023. PMID: 37388759 Free PMC article.
Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis.
Chigutsa E, Velez de Mendizabal N, Chua L, Heathman M, Friedrich S, Jackson K, Reich K. Chigutsa E, et al. Among authors: chua l. J Clin Pharmacol. 2018 Nov;58(11):1489-1500. doi: 10.1002/jcph.1268. Epub 2018 Jun 7. J Clin Pharmacol. 2018. PMID: 29878382 Clinical Trial.
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Jackson K, Chua L, Velez de Mendizabal N, Pitou C, Rodriguez Capriles C, Paller AS, Lansang P, Seyger MMB, Papp K; IXORA-PEDS study group. Jackson K, et al. Among authors: chua l. Br J Clin Pharmacol. 2022 Mar;88(3):1074-1086. doi: 10.1111/bcp.15034. Epub 2021 Sep 2. Br J Clin Pharmacol. 2022. PMID: 34378230 Free PMC article.
312 results